Trump signed an executive order on April 18, 2026, directing the FDA and DEA to fast-track research and approval of ibogaine and psilocybin.

Millions use it for mental health relief. Find out what the science says.

Post-traumatic stress disorder symptoms can overlap with those of other mental health conditions and physical illnesses, like generalized anxiety disorder, major depressive disorder, and cardiovascular disease.

This naturally occurring substance, derived from an African shrub, has been used to treat PTSD, brain trauma, depression, addiction and other disorders.

Experts say President Trump's order, paving the way for scientists to study psychedelic drugs for mental health treatment, has real implications for everyday workers.

NRx Pharmaceuticals has been awarded Fast Track designation and recently received FDA guidance anticipating NRx’s upcoming New Drug Application for NRX-100 (preservative free ketamine) to treat depression, including bipolar depression, in patients who may have suicidal ideation.

The order calls for the FDA to give expedited consideration to certain psychedelic drugs.

December 22, 2008 — The genetic makeup of some individuals makes them substantially more vulnerable than others to develop symptoms of posttraumatic stress disorder (PTSD), anxiety, and depression. A unique study that tracked individuals from 12 ...

President Trump signs a monumental executive order fast-tracking psychedelics for mental health treatment, and ibogaine is repeatedly highlighted. What is ibogaine?